ACM
FBRX icon

ADAR1 Capital Management’s Forte Biosciences FBRX Stock Holding History

ADAR1 Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,000
Closed -$33.5K – 246
2024
Q3 		$33.5K Sell
6,000
-370
-6% -$3.81K 0.01% 230
2024
Q2 		$85.5K Sell
6,370
-450
-7% -$7.27K 0.02% 174
2024
Q1 		$119K Buy
+6,820
New +$119K 0.03% 140

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ADAR1 Capital Management's FBRX Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Forte Biosciences (FBRX) in Q4 2024, closing a stake of 6,000 shares — an estimated $33.5K sold.

ADAR1 Capital Management first reported a position in FBRX in Q1 2024 and held it in 3 quarters. The position peaked at $119K in Q1 2024. 26 funds tracked by Wall St. Rank hold FBRX as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Forte Biosciences position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 6,000 Forte Biosciences shares in Q4 2024, an estimated $33.5K.
  • ADAR1 Capital Management first reported a position in Forte Biosciences in Q1 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Forte Biosciences position peaked at $119K in Q1 2024.
  • 26 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.